RecruitingPhase 1NCT07530289

A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)

A Phase 1, Open-Label, Two-Period Fixed Sequence Study to Evaluate the Effects of a Single Oral Dose of Ulonivirine (MK-8507) on the Single-Dose Pharmacokinetics of Atorvastatin and Metformin in Healthy Adult Participants


Sponsor

Merck Sharp & Dohme LLC

Enrollment

12 participants

Start Date

Apr 29, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Researchers want to learn about ulonivirine when given with atorvastatin and metformin in healthy people. The goal of this study is to compare the amount of atorvastatin and metformin in a person's body over time when given with and without ulonivirine.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria2

  • Has body mass index (BMI) 18.0 and ≤ 32.0 kg/m\^2
  • Is medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and electrocardiogram (ECG)

Exclusion Criteria2

  • Has history of cancer (malignancy)
  • Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtorvastatin

Oral tablet

DRUGMetformin

Oral tablet

DRUGUlonivirine

Oral tablet


Locations(1)

Celerion ( Site 0001)

Tempe, Arizona, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07530289


Related Trials